Lymph node involvement (LNI) in prostate cancer has been associated with decreased cancer-specific survival (CSS) and decreased time of biochemical recurrence.
Lymph node involvement (LNI) in prostate cancer has been associated with decreased cancer-specific survival (CSS) and decreased time of biochemical recurrence. 1, 2 In order to properly evaluate LNI, the pelvic lymph nodes must be removed and pathologically examined. This is because predictive nomograms for LNI based on preoperative criteria have low sensitivity. 3 The pelvic lymph node dissection protocol usually includes the lymph nodes surrounding the internal and external iliac veins, the obturator fossa, the common iliac vein, and the lymphoid tissue in the presacral area. 4 It is not known whether pelvic lymph node dissection has a therapeutic benefit for patients with LNI, but it is well established that it is necessary for staging. 5 The prostatic anterior fat pad (PAFP) had previously not been considered among prostatic lymph drainage sites. 6, 7 Lymphatic drainage from the prostate follows its arterial supply, which mostly enters the prostate posteriorly (middle hemorrhoidal artery, inferior pudendal artery) and superiorly (inferior vesical artery). 8 Therefore, lymphatic drainage is mostly directed to the lymph nodes between the prostate and rectum and towards the lymphatic vessels draining the posterior wall of the urinary bladder. [6] [7] [8] In other studies, the lymphatic drainage of the prostate has been described as draining in three directions: superiorly to the external iliac nodes, laterally to the hypogastric nodes, and posteriorly to the presacral nodes. [9] [10] [11] Recent mapping studies have shown that the vast majority of lymph nodes draining the prostate are located medial to the external iliac veins and posterior to the prostate. 12 The PAFP was initially removed with the sole purpose of visualizing the prostatic apex during radical prostatectomy (RP) and was discarded without pathologic examination. 13 However, in 2007, after detecting positive lymph nodes in the PAFP, a group of researchers demonstrated that the PAFP contained lymph nodes in approximately 10% of cases and showed metastatic involvement in 2% of cases. 13 This raised the question of whether the PAFP should be routinely submitted for pathologic examination. Further studies concluded that the PAFP harbors metastatic disease very rarely, and that this mostly occurs in patients with high preoperative risks for LNI or high preoperative probability of recurrence (D'Amico score). 13, 14 Thus, it has even been suggested that evaluation of the PAFP may not be necessary in cases with low preoperative risk of recurrence and in cases where the tumor does not involve the anterior prostate.
14 This was compounded by recent clinical studies that showed patients with low-grade tumors do not benefit from any form of clinical intervention. 15 Recently, a renewed emphasis has been placed on utilization management in anatomic pathology, which includes, amongst other measures, developing evidence-based protocols to completely forgo the submission of selected specimens for pathologic examination or restrict them to "gross-only" examination. 16 As part of our institution's utilization management initiatives, with the goal of discontinuing services with limited or no clinical value and optimize the utilization of resources in anatomic pathology, we reviewed our experience with the pathologic evaluation of the PAFP. We specifically addressed the question of whether pathologic evaluation of the PAFP can be forgone without resulting in changes in the pathologic staging in cases with low preoperative risk of recurrence.
Materials and Methods

Case Selection
After obtaining institutional review board approval following the guidelines for retrospective studies, we searched our institution's pathology database (Sunquest Copath Plus Version 6.0.0041, Tucson, AZ) for RP specimens processed from January 1, 2009 to November 7, 2017. We excluded cystoprostatectomies for urothelial carcinoma, cases without PAFP, and cases involving malignancies other than prostatic adenocarcinoma. For each RP we recorded the presence of prostatic adenocarcinoma, its Gleason score, International Society of Urological Pathology/ 2016 World Health Organization Grade Group (GG), 17 extent (%) of involvement, the presence of seminal vesicle involvement, perineural invasion, extraprostatic extension, and pathologic T stage. We additionally recorded the total number of lymph nodes examined and lymph nodes involved, N stage, and the presence, number, size, and potential metastatic involvement of any lymph nodes identified in the PAFP. Finally, we measured the size of the metastatic deposits in involved lymph nodes. Only the biopsies and RP specimens of the patients with LNI were re-reviewed. The data of the cases without LNI only were recorded.
From the corresponding preceding prostatic core biopsies, we recorded the total number of cores obtained and their location, the number and location of cores involved by tumor, and the highest Gleason score and GG. Through a search of the electronic medical records (EPIC, Verona, WI), we obtained and recorded prebiopsy prostatic specific antigen (PSA) levels and the clinical stage for all cases showing LNI. We then calculated the D'Amico score from the patient's preoperative PSA, clinical stage, and biopsy Gleason score.
Statistical Analysis
Using RStudio Software V 1.0.153 (SAS Institute, Cary, NC) we performed binomial logistic regression to find correlations between pre-and postoperative variables and the presence of lymph nodes in the PAFP, LNI in the PAFP, and LNI in any site. Preoperative variables were dichotomized: GG were reclassified as low (1-2) and high (3) (4) (5) . Similarly, the number of cores involved was divided into fewer than 50% and 50% or more involved. Confidence intervals (CI) of proportions were calculated using the free calculator GraphPad QuickCalcs (http://www.graphpad.com/quickcalcs). All tests were considered statistically significant when P values were less than .05. The P values presented in the Results section for the nonsignificant variables are for the goodness-of-fit of the binomial logistic regression performed with those variables. The P values presented for the significant variables are for the individual variable when a model is performed using only the significant variables. malignancies other than prostatic adenocarcinoma. The remaining 420 cases were evaluated for pre-and postoperative findings ❚Figure 1❚. The average age of the patients for whom PAFPs were examined pathologically was 59 (95% CI, 59.2-60.6) and the median Gleason score was 7. The preoperative data (biopsy Gleason score, number of cores involved) are summarized in ❚Table 1❚. Most cases were in the low GG 1 and 2 (72.8%; 95% CI, 68.4%-76.8%). Most cases had less than 25% of core involvement (44.4%; 95% CI, 39.4%-48.8%) and the vast majority of cases had less than 50% involvement of the core biopsies (78.6%; 95% CI, 74.4%-82.2%).
The pathology data obtained from the prostatectomies are summarized in ❚Table 2❚. The median Gleason score was 7. Most cases were in GG 1 and 2 (78.1%; 95% CI, 73%-81%). The majority of cases had less than 25% of the prostatic parenchyma involved by tumor (74.7%; 95% CI, 70.8%-78.7%). In 19 cases (4.5%; 95% CI, 2.5%-6.5%) there was LNI. Four cases had LNI in the PAFP (0.95%; 95% CI, 0.28%-2.5%).
Cases With Positive Lymph Nodes
The most commonly involved lymph nodes were the obturator lymph nodes (35.8%; 95% CI, 24.3%-49.3%), followed by the pelvic nodes, the external iliac lymph nodes, and PAFP lymph nodes. The common iliac lymph nodes are considered distant, and when involved the patients are staged as M1a. Those were the least commonly involved nodes (5.7%; 95% CI, 1.3%-15.9%).
Of the four cases with LNI in the PAFP, two had positive lymph nodes only in the PAFP. In one of these cases, the patient had a low D'Amico score, the positive lymph node was nonpalpable (0.2 cm in diameter), and the metastatic deposit was 1 mm in greatest dimension ❚Image 1❚. The second case with LNI only in the PAFP had intermediate D'Amico score and a palpable positive lymph node (0.3 cm in diameter). The other two cases with LNI in the PAFP had concurrent metastatic deposits in other sites. Both of these cases had larger involved lymph nodes, larger metastatic deposits, and high D'Amico scores ❚Image 2❚.
The clinical profile of the patients with LNI showed that most (14/19) had a high D'Amico score. A few had intermediate (4/19) , and only one case had a low D'Amico score. Other clinicopathologic features of the patients with LNI are shown in ❚Table 3❚. Interestingly, the only case with a low D'Amico score had LNI only in the PAFP.
Analysis of Pre-and Postoperative Factors vs LNI
The binomial logistic regression performed on the preoperative data did not demonstrate statistically significant predictive variables for the presence of lymph nodes in the PAFP (P = .679) or LNI in the PAFP (P = .728). Similarly, the postoperative data did not demonstrate statistically significant predictive variables for the presence of lymph nodes in PAFP (P = .328) or LNI in the PAFP (P = .751). The preoperative variables that correlated with LNI in any site were a high GG (P = .016) and a high number of cores involved (P <.001). The goodness of fit test in a binomial logistic regression model with only the significant preoperative predictive factors had a P value of <<.001. The statistically significant postoperative factors were GG (P = .012) and seminal vesicle involvement (P <.001). The goodness of fit test in a binomial logistic regression model with only the significant postoperative predictive factors had a P value of <<.001. Using the model for LNI in any site we calculated the probability of LNI for all N1 cases ❚Table 4❚. 13, 14, [18] [19] [20] [21] [22] [23] Interestingly, the cases with LNI only in the PAFP showed a very low probability of lymph node metastasis using our model. The maximum probability value for LNI was 0.46 for a patient who did not have actual LNI. Of the cases with actual LNI, the minimum probability was 0.005 and the maximum was 0.43 (Table 3) .
Discussion
It has been well established that the incidence of LNI in the PAFP is very low, representing less than 1% of RP cases in most institutions (Table 4 ). Recent studies have also shown that most cases with metastatic disease in the PAFP have a high D'Amico scores. 14, 19, 21 Thus, the utility of routine pathologic examination of the PAFP in patients with low-grade tumors has been questioned. 14 Our study ❚Figure 1❚ Algorithm showing the case selection methodology. LNI, lymph node involvement; PAFP, prostatic anterior prostatic fat; RP, radical prostatectomy.
shows that routine examination of the PAFP cannot be forgone without compromising the accuracy of pathologic staging. We found one case with low D'Amico score that was positive for LNI in the PAFP. This patient was upstaged to N1 solely on the finding of a small metastatic deposit in a tiny, nonpalpable lymph node of the PAFP. We found a second case with LNI only in the PAFP that showed an intermediate D'Amico score. Thus, LNI only in the PAFP was present in two out of 19 cases, representing 11% (95% CI, 2%-32%) of all the N1 cases. Therefore, in our series, despite its rarity, PAFP LNI only was responsible for a significant proportion of lymph node-positive cases. The changes from N0 to N1 based solely of PAFP LNI may cause significant changes in postoperative management. As opposed to other cancer staging systems, the American Joint Committee on Cancer (AJCC) eighth edition, and previous editions, have only a single N1 category to describe any number of involved regional lymph nodes. This reflects the belief that any form of regional nodal involvement represents a systemic disease and implies an adverse outcome, 24 and involvement of more remote (nonregional) lymph nodes (common iliac, aortic, etc.) represents distant metastasis and is staged as M1a. However, it is known that patients with a low volume of LNI have a better CSS than patients with a higher volume of LNI, 25 and a recent study showed that patients with two or more positive lymph nodes have a significantly worse CSS than patients with fewer than two positive nodes. 24 Furthermore, it was shown that patients with single node involvement have a similar CSS to patients with no nodal involvement. Therefore, patients with LNI have a wide range of clinical outcomes, which depends on the extent of LNI. The clinical implications of LNI only in the PAFP in patients with low-grade tumors are most likely very different from those of patients with multiple involved nodes and may also be different from those with single-node involvement in different areas, although the latter has not been studied. Finally, recent clinical studies showing that intervention of any kind in patients with low-grade tumors does not decrease mortality 15 imply that accurate pathologic staging in these may hold no clinical relevance.
Nomograms that include preoperative PSA levels, radiologic findings, and digital rectal examination findings have a low predictive value for LNI identified in RP specimens. 3 In our study we showed that LNI correlated well with preoperative GG and the number and percentage of biopsy cores involved. However, none of the preoperative data we obtained, including highest Gleason score, GG, and number and percentage of biopsy cores involved, correlated with either the presence of lymph nodes in the PAFP or their involvement by metastatic carcinoma. The difficulty in predicting the presence of lymph nodes in the PAFP has been reported previously. 14, 19 However, previous studies have concluded that patients with LNI in the PAFP have a higher pathologic stage, biopsy Gleason score, and D'Amico stage than patients with LNI in other sites. We were unable to show these correlations, possibly due to the low number of cases with LNI in the PAFP in our data set.
Because we did not find any predictive preoperative factors for the presence of lymph nodes in the PAFP or for LNI in the PAFP, we used a regression model to determine the probability of any LNI. This model gave numeric predictions of likelihood of LNI for all cases, including those with involvement of the PAFP lymph nodes. The maximum likelihood was 0.46 and was found for a patient who had 11 of 11 prostate core biopsies involved and a biopsy Gleason score of 10 (5 + 5). However, this patient actually did not have LNI. In general, the model's positive predictive value was low (42.3%). In other words, our model (based on biopsy GG and number of cores involved) was not a very good predictor of LNI. This is in line with larger past studies that have failed to produce reliable preoperative nomograms for LNI. The negative predictive value (98.1%) and specificity (96%) were much better and, therefore, our model is a good predictive tool to correctly classify patients that do not have LNI. Interestingly, the two cases with LNI only in the PAFP had a very low probability of having LNI using our model. This may be further proof that not all forms of LNI should be treated the same, and, in fact, the patients with low-burden and high-burden LNI are treated differently at our institution.
In a review of the literature (including our data) we found a total of 16,887 RP cases that were used to evaluate the utility of processing the PAFP. Of these cases, 1,731 (10.2%; 95% CI, 9.6%-10.8%) had lymph nodes in the PAFP. No significant difference in preoperative variables was identified in any study for lymph node presence in the PAFP. LNI in the PAFP was present in 160 (0.9%; 95 CI, 0.7%-1.0%) cases. Of the cases with LNI in the PFAP, 12 (7.5%; 95% CI, 4.2%-13%) had a low D'Amico score. The summary of the literature review is presented in Table 4 . The populations of patients in the other PAFP studies were similar to our own, with the majority of patients being in the low-risk categories (low biopsy GG and low PSA). Unfortunately, not all studies describe the preoperative variables of the patient population for us to compare.
The strength of this single-institution study is the standardized approach to both prostatectomy and pathologic examination of RP specimens, including the submission of the fat in toto in cases where no palpable lymph nodes are found. The limitations of this study are, in addition to its retrospective design, the relatively low number of cases, which makes it difficult to draw definitive conclusions from the low number of events (PAFP LNI) recorded. Another limitation of our study is that we did not reevaluate all the biopsies and RP specimens included ❚Image 1❚ An involved prostatic anterior fat pad lymph node in a patient with low probability of metastatic disease (×2). The lymph node was grossly not palpable and 1 mm in diameter. The metastatic deposit was less than 0.5 mm in diameter. Inset, a relatively low-grade tumor with glands separated by fibrous stroma (×40).
❚Image 2❚ An involved prostatic anterior fat pad lymph node in a patient with high probability of metastatic disease (×2). The lymph node was grossly palpable and 12 mm in diameter. The metastatic deposit was less than 11 mm in diameter. Inset, a high-grade tumor forming solid sheets of cells with prominent nucleoli (×40).
in this study. In the time frame of this study there have been updates to the histologic criteria of the Gleason score, namely, cribriform pattern being considered Gleason pattern 4 rather than 3. 26 The majority of our cases were from after 2010, therefore most of our cases were graded as currently recommended by the International Society of Urological Pathology. Our results are largely in agreement with previous larger multi-institutional studies and have allowed us to answer the question that led to this study, namely, should we modify our current grossing protocol for RPs. Also, we believe that our results are generalizable to other institutions with a similar surgical patient population. Another potential limitation is the fact that "active surveillance" management strategies have changed in the timeframe of this study. The fact that there may be a requirement for higher biopsy grade for surgical management may have impacted our results. Namely, we may have missed late cases of low-grade tumors with LNI if they were never treated surgically, as they may have been in the past.
The current staging of prostate cancer still holds the logic that any nodal disease represents systemic involvement and does not take into account the extent of nodal involvement. 24 Therefore, according to the AJCC staging system, our patient with low D'Amico score and single nodal involvement is currently staged the same as a patient with a much higher volume of metastatic disease, although they will likely have different clinical outcomes. The relative rarity of PAFP LNI and lack of long-term outcome data suggest that further studies are needed to elucidate the exact significance of PAFP LNI in patients with otherwise low risk of recurrence. Until such studies The probability of LNI was calculated using a binomial logistic regression model for N1 status as a function of ISUP and the number of cores involved.
❚Table 4❚ Review of Literature are performed, we believe that the pathologic processing of the PAFP is required for accurate pathologic staging. Furthermore, because we found metastatic disease in nonpalpable lymph nodes, we recommend processing the tissue using our current protocol, which requires submission of the entire specimens if no lymph nodes are palpated.
